RT Journal Article
T1 Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer.
A1 Ponce Aix, Santiago
A1 Talbot, Denis
A1 Govindan, Ramaswamy
A1 Dols, Manuel Cobo
A1 Postmus, Pieter E
A1 Lewanski, Conrad
A1 Bennouna, Jaafar
A1 Fischer, Juergen R
A1 Juan-Vidal, Oscar
A1 Stewart, David J
A1 Ardizzoni, Andrea
A1 Bhore, Rafia
A1 Wolfsteiner, Marianne
A1 Reck, Martin
A1 Ong, Teng Jin
A1 Morgensztern, Daniel
K1 EORTC QLQ-C30
K1 EQ-5D-5L
K1 durvalumab
K1 lung cancer symptom scale
K1 nab-paclitaxel
K1 non-small cell lung cancer
K1 quality of life
AB Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.
YR 2020
FD 2020-03-31
LK http://hdl.handle.net/10668/15304
UL http://hdl.handle.net/10668/15304
LA en
DS RISalud
RD Apr 17, 2025